High Testosterone in Women: Labs, Diagnosis, and Next Steps

Why Women Develop High Testosterone

Androgen excess in women almost always originates from the ovaries, the adrenal glands, or both. PCOS is the dominant driver, responsible for approximately 72 to 82% of female hyperandrogenism cases in reproductive-age populations according to a 2023 international evidence-based guideline update [1]. The remaining cases split between non-classic congenital adrenal hyperplasia (NCCAH), idiopathic hyperandrogenism, and rare tumors.

The ovaries produce testosterone directly and also synthesize androstenedione, which peripheral tissues convert to testosterone. In PCOS, dysregulated gonadotropin signaling causes theca cells to overproduce androgens. Luteinizing hormone (LH) pulses are faster and higher in amplitude, and insulin acts as a co-gonadotropin that amplifies theca cell steroidogenesis [2]. This is why insulin resistance and hyperandrogenism so often travel together.

Adrenal causes deserve attention when DHEA-S is the predominantly elevated androgen. NCCAH due to 21-hydroxylase deficiency affects roughly 1 in 1,000 individuals of European descent and up to 1 in 100 in Ashkenazi Jewish populations [3]. A morning 17-hydroxyprogesterone level above 200 ng/dL in the follicular phase should prompt an ACTH stimulation test.

Drug-induced hyperandrogenism is frequently overlooked. Valproic acid, danazol, and exogenous testosterone (including compounded "bioidentical" creams applied by a male partner through skin transfer) can raise androgen levels without any underlying glandular pathology.

Recognizing the Clinical Signs

The physical signs of androgen excess show up in specific tissues. Hirsutism (coarse terminal hair in male-pattern areas) is the most common presenting complaint, affecting 5 to 10% of women of reproductive age [4]. A modified Ferriman-Gallwey score of 8 or above on a 36-point scale is considered diagnostic in most populations, though ethnic variation matters. East Asian women may show clinical hyperandrogenism at lower scores.

Acne that persists past the mid-20s, concentrates along the jawline and lower face, and resists topical retinoids often signals androgen-driven sebaceous gland activity. Androgenetic alopecia in women presents as diffuse thinning over the crown with preservation of the frontal hairline, distinct from the bitemporal recession men experience.

Less visible signs include oligomenorrhea or amenorrhea, difficulty conceiving, and acanthosis nigricans (velvety darkening of skin folds that signals insulin resistance). Rapid virilization, meaning voice deepening, clitoromegaly, or sudden severe hirsutism over weeks to months, is a red flag for an androgen-secreting tumor and requires urgent evaluation [5].

Which Labs to Order and When

A targeted lab panel prevents both missed diagnoses and unnecessary spending. Draw all samples in the early morning (before 10 AM) during the follicular phase of the menstrual cycle, ideally days 4 through 10. Hormonal contraceptives must be discontinued for at least 4 to 6 weeks before testing because they suppress gonadotropins and raise sex hormone-binding globulin (SHBG), which artificially lowers free testosterone [1].

The baseline panel should include:

• Total testosterone (by liquid chromatography-tandem mass spectrometry, or LC-MS/MS, not direct immunoassay)
• Free testosterone (calculated from total testosterone, SHBG, and albumin using the Vermeulen equation, or measured by equilibrium dialysis)
• DHEA-S (adrenal androgen marker)
• 17-hydroxyprogesterone (screens for NCCAH)
• LH and FSH (LH:FSH ratio above 2:1 supports PCOS but is not required for diagnosis)
• TSH and prolactin (rule out thyroid dysfunction and hyperprolactinemia as causes of menstrual irregularity)
• Fasting glucose, fasting insulin, and HbA1c (assess metabolic risk)

The 2023 International PCOS Guideline endorsed by the Endocrine Society explicitly recommends LC-MS/MS over immunoassay for testosterone measurement in women because immunoassays lack sensitivity at the low concentrations found in female serum [1]. Dr. Helena Teede, chair of the 2023 guideline development group, stated: "Immunoassays for testosterone in women are unreliable at the low end of the range, and clinical decisions should not rest on them."

If total testosterone exceeds 200 ng/dL or DHEA-S exceeds 700 mcg/dL, imaging is indicated. Transvaginal ultrasound evaluates for ovarian masses, and CT of the adrenal glands rules out adrenal tumors or hyperplasia [5].

Interpreting Your Results

Reference ranges for female testosterone vary between laboratories because different assays produce different numbers. As a general guide, the Endocrine Society considers a total testosterone above 45 to 50 ng/dL (1.6 to 1.7 nmol/L) elevated in premenopausal women when measured by LC-MS/MS [6]. Free testosterone is more diagnostically sensitive. A study of 1,002 women with PCOS and 594 controls found that calculated free testosterone had 85% sensitivity for hyperandrogenism compared to 65% for total testosterone alone [7].

The pattern of androgen elevation helps localize the source:

• Elevated total and free testosterone with normal DHEA-S: ovarian source (likely PCOS)
• Elevated DHEA-S with mildly elevated testosterone: adrenal source (consider NCCAH or adrenal adenoma)
• All androgens markedly elevated: consider mixed source or tumor
• Elevated 17-hydroxyprogesterone (above 200 ng/dL baseline or above 1 to 000 ng/dL post-ACTH stimulation): NCCAH confirmed [3]

A 2019 meta-analysis in the Journal of Clinical Endocrinology and Metabolism (38 studies, N=13,722) determined that the combination of elevated free testosterone plus oligomenorrhea had a positive predictive value of 91% for PCOS diagnosis using Rotterdam criteria [8].

SHBG deserves separate attention. Low SHBG amplifies the biologically active free testosterone fraction even when total testosterone sits in the normal range. Insulin suppresses hepatic SHBG production, so women with metabolic syndrome often present with "normal" total testosterone but high free testosterone. The Endocrine Society's 2008 clinical practice guideline on androgen excess noted: "SHBG is the single most important binding protein influencing androgen bioavailability" [6].

PCOS: The Most Common Cause

PCOS affects 8 to 13% of women of reproductive age worldwide according to a 2023 WHO estimate [9]. Diagnosis follows the Rotterdam criteria, requiring two of three features: oligo-ovulation or anovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasound (12 or more follicles per ovary measuring 2 to 9 mm, or ovarian volume above 10 mL) [1].

Not every woman with PCOS has high testosterone on labs. The 2023 guideline recognizes four phenotypes:

• Phenotype A: hyperandrogenism plus ovulatory dysfunction plus polycystic ovaries (full phenotype)
• Phenotype B: hyperandrogenism plus ovulatory dysfunction
• Phenotype C: hyperandrogenism plus polycystic ovaries
• Phenotype D: ovulatory dysfunction plus polycystic ovaries (no androgen excess)

Phenotypes A and B carry the highest metabolic risk. A longitudinal Australian cohort study (N=8,612, median follow-up 9.1 years) found that women with phenotype A had a 2.4-fold increased risk of type 2 diabetes compared to age-matched controls without PCOS [10]. Metabolic screening is not optional.

Insulin resistance is present in 50 to 70% of women with PCOS regardless of body mass index [2]. Lean women with PCOS are not metabolically exempt.

Treatment: Addressing the Cause and the Symptoms

Treatment strategy depends on whether the patient wants to manage symptoms, conceive, or both. No single drug addresses every manifestation.

Combined oral contraceptives (COCs) are first-line for menstrual regulation and androgen suppression. The estrogen component raises SHBG (reducing free testosterone), and the progestin opposes unopposed estrogen on the endometrium. Pills containing anti-androgenic progestins (drospirenone, cyproterone acetate, or dienogest) offer additional benefit for hirsutism and acne [1]. A Cochrane review of 9 trials (N=502) found that COCs reduced Ferriman-Gallwey scores by an average of 4.9 points over 6 to 12 months compared to placebo [11].

Spironolactone (50 to 200 mg daily) is the most widely used androgen receptor blocker in the United States for female hyperandrogenism. It blocks the androgen receptor directly and mildly inhibits 5-alpha reductase. Because it is teratogenic (risk of feminization of a male fetus), reliable contraception is mandatory during use. Results for hirsutism take 6 to 9 months to become apparent because of the hair growth cycle [4].

Metformin (1,500 to 2 to 000 mg daily) improves insulin sensitivity and modestly lowers androgen levels. The 2023 PCOS guideline recommends metformin alongside lifestyle modification for metabolic features, particularly in women with BMI above 25 kg/m² or impaired glucose tolerance [1]. A randomized trial (N=626) showed that metformin reduced total testosterone by 11.2% and improved ovulation rates compared to placebo over 6 months [12].

Lifestyle modification (structured exercise and dietary adjustment targeting 5 to 10% weight loss in women with overweight or obesity) reduces free testosterone by up to 20% and can restore ovulatory cycles in some women. The 2023 guideline recommends 150 minutes per week of moderate-intensity exercise regardless of BMI [1].

For women trying to conceive, letrozole (an aromatase inhibitor) is first-line for ovulation induction in PCOS. The PPCOS II trial (N=750) demonstrated a 27.5% live birth rate with letrozole versus 19.1% with clomiphene citrate (P<0.007) [13].

When to Refer to a Specialist

A primary care provider can manage straightforward PCOS. But certain findings require endocrinology, gynecology, or reproductive endocrinology referral.

Refer urgently if total testosterone exceeds 200 ng/dL, if DHEA-S exceeds 700 mcg/dL, or if virilization is progressing rapidly (over weeks rather than years). These patterns suggest androgen-secreting ovarian or adrenal tumors, which occur in roughly 0.2% of hyperandrogenic women but carry significant morbidity if missed [5].

Refer for subspecialty input if 17-hydroxyprogesterone is elevated and NCCAH needs confirmation via ACTH stimulation testing, if the patient desires fertility and has not conceived after 6 months of ovulation induction in primary care, or if hyperandrogenism persists despite 12 months of COC plus spironolactone therapy.

Postmenopausal women with new-onset hyperandrogenism represent a distinct population. Ovarian hyperthecosis (bilateral stromal hyperplasia) and Sertoli-Leydig cell tumors are more common in this age group, and testosterone levels can exceed 150 ng/dL. Pelvic MRI and selective venous sampling may be needed [14].

Monitoring and Long-Term Follow-Up

After starting treatment, recheck total and free testosterone at 3 months, then every 6 to 12 months once stable. For women on spironolactone, monitor potassium and creatinine at baseline, at 1 month, then annually, because the drug is a potassium-sparing diuretic [4].

Metabolic screening should be repeated every 1 to 3 years in women with PCOS: fasting glucose or oral glucose tolerance test (OGTT is preferred over HbA1c for PCOS per the 2023 guideline), lipid panel, and blood pressure [1]. Women with PCOS who are not on cyclic progestin or COCs should have endometrial thickness assessed if they go more than 90 days without a menstrual period, given the increased risk of endometrial hyperplasia from unopposed estrogen.

Mental health screening is now a formal recommendation. The 2023 guideline mandates screening for anxiety and depression at diagnosis and periodically thereafter, citing prevalence rates of 34% for anxiety and 40% for depressive symptoms in PCOS populations [1].

Schedule a repeat total testosterone 6 weeks after discontinuing any hormonal contraceptive if reassessment of the underlying androgen status is needed.